Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy
Open accessThe DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Abstract
Accumulating evidence supports not only the functional role of the gut microbiome in cancer development and progression but also its role in defining the efficacy and toxicity of chemotherapeutic agents (5-fluorouracil, cyclophosphamide, irinotecan, oxaliplatin, gemcitabine, methotrexate) and immunotherapeutic compounds (anti-programmed death-ligand 1/anti-programmed cell death protein 1 and anti-cytotoxic T-lymphocyte-associated antigen 4). This evidence is supported in numerous in vitro, animal, and clinical studies that highlight the importance of microbial mechanisms in defining therapeutic responses. The microbiome therefore shapes oncologic outcomes and is now being leveraged for the development of novel personalized therapeutic approaches in cancer treatment. However, if the microbiome is to be successfully translated into next-generation oncologic treatments, a new multimodal model of the oncomicrobiome must be conceptualized that incorporates gut microbial cometabolism of pharmacologic agents into cancer care. The objective of this review is therefore to outline the current knowledge of oncologic pharmacomicrobiomics and to describe how the multiparametric functions of the gut microbiome influence treatment response across cancer types. The secondary objective is to propose innovative approaches for modulating the gut microbiome in clinical environments that improve therapy efficacy and diminish toxic effects derived from antineoplastic agents for patient benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Interaction between microbiota and immunity in health and disease
Zheng, D., Liwinski, T., & Elinav, E. (2020) · Cell Research · doi:10.1038/s41422-020-0332-7 · Cited by 3,947
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.008 · Cited by 2,198
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z. A., Shee, K., et al. (2017) · Science · doi:10.1126/science.aah5043 · Cited by 1,817
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., et al. (2020) · Science · doi:10.1126/science.abc3421 · Cited by 1,407
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
Mapping human microbiome drug metabolism by gut bacteria and their genes
Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., & Goodman, A. L. (2019) · Nature · doi:10.1038/s41586-019-1291-3 · Cited by 1,160
A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
Tanoue, T., Morita, S., Plichta, D. R., Skelly, A. N., Suda, W., Sugiura, Y., Narushima, S., Vlamakis, H., Motoo, I., Sugita, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0878-z · Cited by 1,145
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987
Next-generation probiotics: the spectrum from probiotics to live biotherapeutics
O’Toole, P. W., Marchesi, J. R., & Hill, C. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.57 · Cited by 971
Self-citationGut microbiota modulation of chemotherapy efficacy and toxicity
Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.20 · Cited by 970
Self-citationPreventing and Managing Toxicities of High-Dose Methotrexate
Howard, S. C., McCormick, J., Pui, C.-H., Buddington, R. K., & Harvey, R. D. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0164 · Cited by 929
Daillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., Duong, C. P. M., Flament, C., Lepage, P., Roberti, M. P., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.009 · Cited by 897
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0238-9 · Cited by 740
He, Y., Fu, L., Li, Y., Wang, W., Gong, M., Zhang, J., Dong, X., Huang, J., Wang, Q., Mackay, C. R., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.002 · Cited by 729
Programmable bacteria induce durable tumor regression and systemic antitumor immunity
Chowdhury, S., Castro, S., Coker, C., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2019) · Nature Medicine · doi:10.1038/s41591-019-0498-z · Cited by 724
Ou, J., Carbonero, F., Zoetendal, E. G., DeLany, J. P., Wang, M., Newton, K., Gaskins, H. R., & O’Keefe, S. J. (2013) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.056689 · Cited by 646
Huang, J., Liu, D., Wang, Y., Liu, L., Li, J., Yuan, J., Jiang, Z., Jiang, Z., Hsiao, W. W., Liu, H., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-321031 · Cited by 539
Chemotherapy‐driven dysbiosis in the intestinal microbiome
Montassier, E., Gastinne, T., Vangay, P., Al‐Ghalith, G. A., Bruley des Varannes, S., Massart, S., Moreau, P., Potel, G., de La Cochetière, M. F., Batard, E., et al. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13302 · Cited by 515
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
Coutzac, C., Jouniaux, J.-M., Paci, A., Schmidt, J., Mallardo, D., Seck, A., Asvatourian, V., Cassard, L., Saulnier, P., Lacroix, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16079-x · Cited by 513
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Andrews, M. C., Duong, C. P. M., Gopalakrishnan, V., Iebba, V., Chen, W.-S., Derosa, L., Khan, M. A. W., Cogdill, A. P., White, M. G., Wong, M. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01406-6 · Cited by 437
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Liu, J., Chen, Z., Li, Y., Zhao, W., Wu, J., & Zhang, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.731798 · Cited by 417
Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling
Shi, Y., Zheng, W., Yang, K., Harris, K. G., Ni, K., Xue, L., Lin, W., Chang, E. B., Weichselbaum, R. R., & Fu, Y.-X. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20192282 · Cited by 409
Österlund, P., Ruotsalainen, T., Korpela, R., Saxelin, M., Ollus, A., Valta, P., Kouri, M., Elomaa, I., & Joensuu, H. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603990 · Cited by 405
Matson, V., Chervin, C. S., & Gajewski, T. F. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.11.041 · Cited by 385
Kakihana, K., Fujioka, Y., Suda, W., Najima, Y., Kuwata, G., Sasajima, S., Mimura, I., Morita, H., Sugiyama, D., Nishikawa, H., et al. (2016) · Blood · doi:10.1182/blood-2016-05-717652 · Cited by 367
Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy
Górska, A., Przystupski, D., Niemczura, M. J., & Kulbacka, J. (2019) · Current Microbiology · doi:10.1007/s00284-019-01679-8 · Cited by 344
The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Response
Sánchez-Alcoholado, L., Ramos-Molina, B., Otero, A., Laborda-Illanes, A., Ordóñez, R., Medina, J. A., Gómez-Millán, J., & Queipo-Ortuño, M. I. (2020) · Cancers · doi:10.3390/cancers12061406 · Cited by 337
Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview
Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S., Seeber, S., & Rustum, Y. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1501 · Cited by 326
Fecal microbiota transplantation in cancer management: Current status and perspectives
Chen, D., Wu, J., Jin, D., Wang, B., & Cao, H. (2019) · International Journal of Cancer · doi:10.1002/ijc.32003 · Cited by 321
Si, W., Liang, H., Bugno, J., Xu, Q., Ding, X., Yang, K., Fu, Y., Weichselbaum, R. R., Zhao, X., & Wang, L. (2022) · Gut · doi:10.1136/gutjnl-2020-323426 · Cited by 321
Vernieri, C., Fucà, G., Ligorio, F., Huber, V., Vingiani, A., Iannelli, F., Raimondi, A., Rinchai, D., Frigè, G., Belfiore, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0030 · Cited by 319
Local bacteria affect the efficacy of chemotherapeutic drugs
Lehouritis, P., Cummins, J., Stanton, M., Murphy, C. T., McCarthy, F. O., Reid, G., Urbaniak, C., Byrne, W. L., & Tangney, M. (2015) · Scientific Reports · doi:10.1038/srep14554 · Cited by 313
Oncolytic virus immunotherapy: future prospects for oncology
Raja, J., Ludwig, J. M., Gettinger, S. N., Schalper, K. A., & Kim, H. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0458-z · Cited by 313
An atlas of β-glucuronidases in the human intestinal microbiome
Pollet, R. M., D'Agostino, E. H., Walton, W. G., Xu, Y., Little, M. S., Biernat, K. A., Pellock, S. J., Patterson, L. M., Creekmore, B. C., Isenberg, H. N., et al. (2017) · Structure · doi:10.1016/j.str.2017.05.003 · Cited by 289
Scott, A. J., Alexander, J. L., Merrifield, C. A., Cunningham, D., Jobin, C., Brown, R., Alverdy, J., O’Keefe, S. J., Gaskins, H. R., Teare, J., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318556 · Cited by 288
Self-citationGut microbiota is critical for the induction of chemotherapy-induced pain
Shen, S., Lim, G., You, Z., Ding, W., Huang, P., Ran, C., Doheny, J., Caravan, P., Tate, S., Hu, K., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4606 · Cited by 286
The Role of Probiotics in Cancer Prevention
Śliżewska, K., Markowiak-Kopeć, P., & Śliżewska, W. (2020) · Cancers · doi:10.3390/cancers13010020 · Cited by 282
Panax ginseng—a non-organ-specific cancer preventive?
Yun, T.-K. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00196-0 · Cited by 276
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 274
Potential of probiotics, prebiotics and synbiotics for management of colorectal cancer
Raman, M., Ambalam, P., Kondepudi, K. K., Pithva, S., Kothari, C., Patel, A. T., Purama, R. K., Dave, J. M., & Vyas, B. R. M. (2013) · Gut Microbes · doi:10.4161/gmic.23919 · Cited by 268
Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model.
Gui, Q.-F., Lu, H.-F., Zhang, C.-X., Xu, Z.-R., & Yang, Y.-H. (2015) · Genetics and Molecular Research · doi:10.4238/2015.may.25.16 · Cited by 262
Host-microbe co-metabolism dictates cancer drug efficacy in C. elegans
Scott, T. A., Quintaneiro, L. M., Norvaisas, P., Lui, P. P., Wilson, M. P., Leung, K.-Y., Herrera-Dominguez, L., Sudiwala, S., Pessia, A., Clayton, P. T., et al. (2017) · Cell · doi:10.1016/j.cell.2017.03.040 · Cited by 254
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
Pan, C., Liu, H., Robins, E., Song, W., Liu, D., Li, Z., & Zheng, L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00862-w · Cited by 241
Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade
Wang, F., Yin, Q., Chen, L., & Davis, M. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712901115 · Cited by 223
Selma, M. V., Beltrán, D., Luna, M. C., Romo-Vaquero, M., García-Villalba, R., Mira, A., Espín, J. C., & Tomás-Barberán, F. A. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01521 · Cited by 211
Botticelli, A., Vernocchi, P., Marini, F., Quagliariello, A., Cerbelli, B., Reddel, S., Del Chierico, F., Di Pietro, F., Giusti, R., Tomassini, A., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02231-0 · Cited by 209
The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease
Staffas, A., Burgos da Silva, M., & van den Brink, M. R. M. (2017) · Blood · doi:10.1182/blood-2016-09-691394 · Cited by 208
VSL#3 probiotic treatment reduces chemotherapy-induced diarrhoea and weight loss
Bowen, J. M., Stringer, A. M., Gibson, R. J., Yeoh, A. S., Hannam, S., & Keefe, D. M. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.9.4622 · Cited by 202
Metabolome analysis for investigating host-gut microbiota interactions
Chen, M. X., Wang, S.-Y., Kuo, C.-H., & Tsai, I.-L. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.09.007 · Cited by 192
Probiotics, prebiotics and synbiotics: A role in chemoprevention for colorectal cancer?
Geier, M. S., Butler, R. N., & Howarth, G. S. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.10.3296 · Cited by 184
Yeung, C.-Y., Chan, W.-T., Jiang, C.-B., Cheng, M.-L., Liu, C.-Y., Chang, S.-W., Chiang Chiau, J.-S., & Lee, H.-C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138746 · Cited by 176
Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience
Sougiannis, A. T., VanderVeen, B. N., Davis, J. M., Fan, D., & Murphy, E. A. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00380.2020 · Cited by 176
Molecular mechanisms of postbiotics in colorectal cancer prevention and treatment
Rad, A. H., Aghebati-Maleki, L., Kafil, H. S., & Abbasi, A. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1765310 · Cited by 165
Vemuri, R., Shankar, E. M., Chieppa, M., Eri, R., & Kavanagh, K. (2020) · Microorganisms · doi:10.3390/microorganisms8040483 · Cited by 162
Irinotecan (CPT-11) Chemotherapy Alters Intestinal Microbiota in Tumour Bearing Rats
Lin, X. B., Dieleman, L. A., Ketabi, A., Bibova, I., Sawyer, M. B., Xue, H., Field, C. J., Baracos, V. E., & Gänzle, M. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039764 · Cited by 159
Strumberg, D., Awada, A. H., Hirte, H. W., Clark, J. W., Seeber, S., Piccart, P., Hofstra, E., Voliotis, D., Christensen, O., Brueckner, A., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.014 · Cited by 154
Ma, J., Huang, L., Hu, D., Zeng, S., Han, Y., & Shen, H. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02128-w · Cited by 153
Phase-II metabolism limits the antiproliferative activity of urolithins in human colon cancer cells
González‐Sarrías, A., Giménez‐Bastida, J. A., Núñez‐Sánchez, M. Á., Larrosa, M., García‐Conesa, M., Tomás-Barberán, F. A., & Espín, J. C. (2013) · European Journal of Nutrition · doi:10.1007/s00394-013-0589-4 · Cited by 148
Ou, J., DeLany, J. P., Zhang, M., Sharma, S., & O’Keefe, S. J. D. (2012) · Nutrition and Cancer · doi:10.1080/01635581.2012.630164 · Cited by 144
The gut microbiome: what the oncologist ought to know
Lee, K. A., Luong, M. K., Shaw, H., Nathan, P., Bataille, V., & Spector, T. D. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01467-x · Cited by 143
Motoori, M., Yano, M., Miyata, H., Sugimura, K., Saito, T., Omori, T., Fujiwara, Y., Miyoshi, N., Akita, H., Gotoh, K., et al. (2015) · Clinical Nutrition · doi:10.1016/j.clnu.2015.11.008 · Cited by 135
Gut microbiota as important modulator of metabolism in health and disease
Wang, X., Zhang, A., Miao, J.-H., Sun, H. J., Yan, G., Wu, F., & Wang, X.-J. (2018) · RSC Advances · doi:10.1039/c8ra08094a · Cited by 117
Hsiao, Y., Chen, H., Tsai, J., Lin, M., Liao, J., Wei, M.-S., Ko, J., & Ou, C. (2021) · Nutrients · doi:10.3390/nu13082792 · Cited by 108
Postbiotics as Promising Tools for Cancer Adjuvant Therapy
Rad, A. H., Maleki, L. A., Kafil, H. S., Zavoshti, H. F., & Abbasi, A. (2020) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2021.007 · Cited by 106
Tang, Y., Wu, Y., Huang, Z., Dong, W., Deng, Y., Wang, F., Li, M., & Yuan, J. (2016) · Nutrition · doi:10.1016/j.nut.2016.05.003 · Cited by 104
Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells
Encarnação, J. C., Pires, A. S., Amaral, R. A., Gonçalves, T. J., Laranjo, M., Casalta‐Lopes, J., Gonçalves, A. C., Sarmento‐Ribeiro, A. B., Abrantes, A. M., & Botelho, M. F. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.02.018 · Cited by 103
Microbiota-driven mechanisms at different stages of cancer development
Ivleva, E., & Grivennikov, S. I. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100829 · Cited by 103
Mi, H., Dong, Y., Zhang, B., Wang, H., Peter, C. C. K., Gao, P., Fu, H., & Gao, Y. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000480005 · Cited by 102
Gong, S., Feng, Y., Zeng, Y., Zhang, H., Pan, M., He, F., Wu, R., Chen, J., Lu, J., Zhang, S., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02814-5 · Cited by 98
TLR Signaling Modulates Side Effects of Anticancer Therapy in the Small Intestine
Frank, M., Hennenberg, E. M., Eyking, A., Rünzi, M., Gerken, G., Scott, P., Parkhill, J., Walker, A. W., & Cario, E. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402481 · Cited by 97
Lin, X. B., Farhangfar, A., Valcheva, R., Sawyer, M. B., Dieleman, L., Schieber, A., Gänzle, M. G., & Baracos, V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083644 · Cited by 96
Smith, C. L., Geier, M. S., Yazbeck, R., Torres, D. M., Butler, R. N., & Howarth, G. S. (2008) · Nutrition and Cancer · doi:10.1080/01635580802192841 · Cited by 93
Justino, P. F. C., Melo, L. F. M., Nogueira, A. F., Morais, C. M., Mendes, W. D. O., Franco, Á. X., de Souza, E. P., Ribeiro, R. A., de Souza, M. H. L. P., & Soares, P. M. G. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2663-x · Cited by 91
Kong, R., Liu, T., Zhu, X., Ahmad, S., Williams, A. L., Phan, A. T., Zhao, H., Scott, J. E., Yeh, L.-A., & Wong, S. T. C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0395 · Cited by 90
Forsgård, R. A., Marrachelli, V. G., Korpela, K., Frías, R., Collado, M. C., Korpela, R., Monleón, D., Spillmann, T., & Osterlund, P. J. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3364-z · Cited by 86
Anti-Colorectal Cancer Chemotherapy-Induced Diarrhoea: Current Treatments and Side-Effects
McQuade, R. M., Bornstein, J. C., & Nurgali, K. (2014) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2014.57054 · Cited by 83
Okawa, T., Niibe, H., Arai, T., Sekiba, K., Noda, K., Takeuchi, S., Hashimoto, S., & Ogawa, N. (1993) · Cancer · doi:10.1002/1097-0142(19930915)72:6<1949::aid-cncr2820720626>3.0.co;2-w · Cited by 82
Potential Impacts of Prebiotics and Probiotics on Cancer Prevention
Samanta, S. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621999201210220442 · Cited by 82
CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials
Zhang, Z., Kuo, J. C., Yao, S., Zhang, C., Khan, H., & Lee, R. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010073 · Cited by 79
Bronckaers, A., Balzarini, J. M., & Liekens, S. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.04.019 · Cited by 77
Kato, S., Hamouda, N., Kano, Y., Oikawa, Y., Tanaka, Y., Matsumoto, K., Amagase, K., & Shimakawa, M. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12792 · Cited by 74
Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy
Li, R., Helbig, L., Fu, J., Bian, X., Herrmann, J., Baumann, M., Stewart, A. F., Müller, R., Li, A., Zips, D., et al. (2019) · Research in Microbiology · doi:10.1016/j.resmic.2018.11.001 · Cited by 73
Koschny, R., Gotthardt, D. N., Koehler, C., Jaeger, D., Stremmel, W., & Ganten, T. M. (2012) · Oncology · doi:10.1159/000342425 · Cited by 68
Secreted human β-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy
Weyel, D., Sedlacek, H.-H., Müller, R., & Brüsselbach, S. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301072 · Cited by 64
Paquet, J.-C., Claus, S. P., Cordaillat‐Simmons, M., Mazier, W., Rawadi, G., Rinaldi, L., Elustondo, F., & Rouanet, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.716266 · Cited by 60
Quaresma, M. P., Damasceno, S., Monteiro, C. E. D. S., Lima, F. J. B., Mendes, T. S., Lima, M. D. S., Justino, P. F. C., Barbosa, A. L. D. R., de Souza, M. H. L. P., de Souza, E. P., et al. (2019) · Nutrition and Cancer · doi:10.1080/01635581.2019.1675719 · Cited by 45
Wang, L., Wang, R., Wei, G.-Y., Shu-me, W., & Du, G. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110262 · Cited by 44
Galdino, F. M. P., Andrade, M. E. R., de Barros, P. A. V., Generoso, S. D. V., Alvarez-Leite, J. I., Almeida‐Leite, C. M., Pelúzio, M. D. C. G., Fernandes, S. O. A., & Cardoso, V. N. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.09.012 · Cited by 43
Huisman, S. A., Bijman-Lagcher, W., IJzermans, J. N., Smits, R., & de Bruin, R. W. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1044170 · Cited by 42
Nontoxic Potentiation of Cancer Chemotherapy by Dietary Oligofructose or Inulin
Taper, H. S., & Roberfroid, M. B. (2000) · Nutrition and Cancer · doi:10.1207/s15327914nc381_1 · Cited by 42
Ma, D. C., Anderson, C. M., Rodman, S. N., Buranasudja, V., McCormick, M. L., Davis, A. B., Loth, E., Bodeker, K. L., Ahmann, L., Parkhurst, J. R., et al. (2021) · Radiation Research · doi:10.1667/rade-20-00150.1 · Cited by 40
Oh, N. S., Lee, J. Y., Lee, J. M., Lee, K., & Kim, Y. (2017) · Letters in Applied Microbiology · doi:10.1111/lam.12741 · Cited by 38
Yuan, W., Xiao, X., Yu, X., Xie, F., Feng, P., Malik, K., Wu, J., Ye, Z., Zhang, P., & Li, X. (2021) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-021-09795-3 · Cited by 37
Porto, B. A., Monteiro, C. F., Souza, É. L. D. S. E., Leocádio, P. C. L., Alvarez-Leite, J. I., Generoso, S. D. V., Cardoso, V. N., Almeida‐Leite, C. M., Santos, D. A., dos Santos, J. R. A., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03865-8 · Cited by 36
Kim, S., Park, A. K., Chaurasiya, S., Kang, S., Lü, J., Yang, A., Sivanandam, V., Zhang, Z., Woo, Y., Priceman, S. J., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0405 · Cited by 33
Engineered Bacteriophage T7 as a Potent Anticancer Agent in vivo
Hwang, Y. J., & Myung, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.491001 · Cited by 31
Faber, J., van Limpt, K., Kegler, D., Luiking, Y. C., Garssen, J., van Helvoort, A., Vos, A. P., & Knol, J. (2011) · Journal of Nutrition · doi:10.3945/jn.110.136986 · Cited by 28
Yassin, M. A., Ghasoub, R. S., Aldapt, M. B., Abdulla, M. A.-J., Chandra, P., Shwaylia, H. M., Nashwan, A. J., Kassem, N. A., & Akiki, S. J. (2021) · Cancer Control · doi:10.1177/10732748211009256 · Cited by 28
Zhuang, H., Jing, N., Wang, L., Jiang, G., & Liu, Z. (2021) · Nutrients · doi:10.3390/nu13082700 · Cited by 26
Rad, A. H., Maleki, L. A., Kafil, H. S., Abbasi, A., & Khani, N. (2021) · Scientific Journal of Kurdistan University of Medical Sciences · doi:10.52547/sjku.26.4.132 · Cited by 25
Discovery of Bacterial Deaminases That Convert 5-Fluoroisocytosine Into 5-Fluorouracil
Aučynaitė, A., Rutkienė, R., Tauraitė, D., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02375 · Cited by 21
Gut microbiome and checkpoint inhibitor colitis
Sehgal, K., & Khanna, S. (2020) · Intestinal Research · doi:10.5217/ir.2020.00116 · Cited by 21
Antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC).
Lalani, A. A., Xie, W., Lin, X., Steinharter, J. A., Martini, D. J., Duquette, A., Bossé, D., McKay, R. R., Simantov, R., Wei, X. X., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.607 · Cited by 16
Bacterial treatment for cancer
Lokody, I. B. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3827 · Cited by 9
Oudmaijer, C. A. J., Berk, K. A., van der Louw, E. J. T. M., de Man, R., van der Lelij, A., Hoeijmakers, J. H. J., & IJzermans, J. N. M. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-053559 · Cited by 6
Chambers, L., Esakov, E. L., Braley, C., Trestan, L., Alali, Z., Bayık, D., Lathia, J. D., Sangwan, N., Bazeley, P. S., Joehlin-Price, A. S., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-80626/v2 · Cited by 2
Cited by
TTD: Therapeutic Target Database describing target druggability information
Zhou, Y., Zhang, Y., Zhao, D., Yu, X., Shen, X., Zhou, Y., Wang, S., Qiu, Y., Chen, Y., & Zhu, F. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad751 · Cited by 645
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Metadata
- Authors
- Chrysostomou, D., Roberts, L. A., Marchesi, J. R., & Kinross, J. M.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2023-02
- Volume
- 164
- Issue
- 2
- Pages
- 198-213
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W4307564407
- Cited by
- 283
- References
- 117
- FWCI
- 14.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.